Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 known ✓ | P22894 | 2/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.53 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 3/20 | 0.47 |
| ▸ | MMP9 | P14780 | 2/20 | 0.46 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6396386 | 1.00 | SLC1A3 (0.53) | SLC1A3SLC1A2SLC1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6232177 | 1.00 | SLC1A3 (0.53) | SLC1A3SLC1A2SLC1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL30751687 | 1.00 | SLC1A3 (0.53) | SLC1A3SLC1A2SLC1A1MEN1KMT2A | |
| SCHEMBL1631287 | 0.98 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1MEN1KMT2A | |
| SCHEMBL27818355 | 0.98 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1MEN1KMT2A | |
| SCHEMBL5196487 | 0.98 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1MEN1KMT2A | |
| SCHEMBL1631290 | 0.98 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL19614462 | 0.89 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL19614463 | 0.89 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL19614467 | 0.89 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12065445-B2 | CDK2 inhibitors and methods of using the same | CEDILLA THERAPEUTICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20240174680-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| EP-4284365-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-117177744-A | CDK2 inhibitors and methods of use thereof | 塞迪拉治疗股份有限公司 | 2023-12-05 | — | — | CN | disclosed |
| US-20230109076-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2022165513-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| US-9701684-B2 | Chiral fluorinating reagents | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-07-11 | — | — | US | disclosed |
| US-20150284401-A1 | CHIRAL FLUORINATING REAGENTS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2015-10-08 | — | — | US | disclosed |
| US-20050282824-A1 | Substituted pyrimidines as inhibitors of bacterial type III protein secretion systems | LI XIAOBING | 2005-12-22 | — | — | US | disclosed |
| WO-2005113514-A2 | SUBSTITUTED PYRIMIDINES AS INHIBITORS OF BACTERIAL TYPE III PROTEIN SECRETION SYSTEMS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-12-01 | — | — | WO | disclosed |
| US-6927290-B2 | Production of mixed acid anhydride and amide compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-08-09 | — | — | US | disclosed |
| EP-1160236-B1 | Production of mixed acid anhydride and amine compound | SUMITOMO CHEMICAL CO (JP) | 2005-05-25 | — | — | EP | disclosed |
| US-20040210059-A1 | Production of mixed acid anhydride and amide compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-10-21 | — | — | US | disclosed |
| US-6753431-B2 | REACTING A CARBAMATE DERIVATIVE WITH CARBOXYLIC AND HALOFORMIC ACID DERIVATIVES | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2004-06-22 | — | — | US | disclosed |
| EP-0900211-B1 | THIADIAZOLYL(THIO)UREAS USEFUL AS MATRIX METALLOPROTEASE INHIBITORS | UPJOHN CO (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20020032346-A1 | Production of mixed acid anhydride and amide compound | SUMITOMO CHEMICAL CO., LTD. | 2002-03-14 | — | — | US | disclosed |
| EP-1160236-A2 | Production of mixed acid anhydride and amine compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-12-05 | — | — | EP | disclosed |
| EP-0900211-A1 | THIADIAZOLYL(THIO)UREAS USEFUL AS MATRIX METALLOPROTEASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1999-03-10 | — | — | EP | disclosed |
| US-5847148-A | Thiadiazole derivatives useful for the treatment of diseases related to connective tissue degradation | PHARMACIA & UPJOHN COMPANY (US) | 1998-12-08 | — | — | US | disclosed |
| WO-1997040031-A1 | THIADIAZOLYL(THIO)UREAS USEFUL AS MATRIX METALLOPROTEASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284401-A1 | CHIRAL FLUORINATING REAGENTS | TIAM1, AFF2, AFF1 | MMP8 3974/4885SLC1A3 2806/4885SLC1A2 2631/4885 |
| US-20240174680-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | MMP8 3715/4885SLC1A3 4698/4885SLC1A2 4724/4885 |
| US-20230109076-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | MMP8 3715/4885SLC1A3 4698/4885SLC1A2 4724/4885 |
| US-20040210059-A1 | Production of mixed acid anhydride and amide compound | CA2, CA1, CA3 | MMP8 4488/4885SLC1A3 1447/4885SLC1A2 1114/4885 |
| US-20050282824-A1 | Substituted pyrimidines as inhibitors of bacterial type III protein secretion systems | UMPS, NUDT14, NUDT5 | MMP8 2067/4885SLC1A3 882/4885SLC1A2 2825/4885 |
| US-20020032346-A1 | Production of mixed acid anhydride and amide compound | CA2, CA1, CA3 | MMP8 4488/4885SLC1A3 1447/4885SLC1A2 1114/4885 |
| US-12065445-B2 | CDK2 inhibitors and methods of using the same | CDK2, CDK20, CDK1 | MMP8 3752/4885SLC1A3 4487/4885SLC1A2 4545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.